Brief: Viking Therapeutics Q2 EPS USD -1.1 Vs. IBES Estimate USD -1.25
29/07/2026 21:06
BRIEF-Viking Therapeutics Q2 EPS USD -1.1 Vs. IBES Estimate USD -1.25 Jul 29 (Reuters) - Viking Therapeutics Q2 operating expenses USD 132.597 million.
- Q2 income from operations USD -132.597 million vs. IBES estimate USD -150.3 million
- Q2 net income USD -128.022 million vs. IBES estimate USD -144.7 million
Recent news on Viking Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry